Literature DB >> 29571786

Dynamic contrast enhanced magnetic resonance lymphangiography: Categorization of imaging findings and correlation with patient management.

Sheena Pimpalwar1, Ponraj Chinnadurai2, Alex Chau3, Mercedes Pereyra4, Daniel Ashton5, Prakash Masand6, Rajesh Krishnamurthy7, Siddharth Jadhav8.   

Abstract

OBJECTIVE: To review the technical aspects and categorize the imaging findings of dynamic contrast enhanced magnetic resonance lymphangiography (DCMRL) and correlate the findings with patient management options.
MATERIALS AND METHODS: A retrospective review of patients who underwent DCMRL between June 2012 and August 2017 at a tertiary care paediatric hospital was performed. Twenty-five DCMRL studies were performed in 23 patients (9 males, 13 females, 1 ambiguous gender) with a median age of 4 years (range: 1 month-29 years). DCMRL imaging findings were reviewed, categorized and the impact on patient management was studied.
RESULTS: DCMRL was technically successful in 23/25 (92%) studies. DCMRL findings were categorized based on the status of central conducting lymphatics (CCL) and alternate lymphatic pathways as follows: Type 1 - normal CCL with no alternate lymphatic pathways, Type 2 - partial (2a) or complete (2b) non-visualization of CCL with reflux of contrast into alternate pathways and Type 3 - normal CCL with additional filling of alternate pathways. Type 1 DCMRL patients (n = 5) were reassured and conservative management was continued, Type 2 patients (n = 10) had evidence of CCL obstruction hence thoracic duct ligation or embolization was avoided and other options such as lymphatic fluid diversion using Denver® shunt or lympho-venous anastomosis were used, and Type 3 patients (n = 8) were evaluated for elevated central venous pressure as a cause of lymphatic backflow in addition to Denver® shunt, lympho-venous anastomosis, thoracic duct ligation or embolization.
CONCLUSION: DCMRL is an evolving imaging technique for understanding abnormalities of the central conducting lymphatics. Categorization of imaging findings may be helpful in guiding selection of management options.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Central conducting lymphatics; Chylothorax; Chylous ascites; Intra-nodal lymphangiography; MR lymphangiography

Mesh:

Substances:

Year:  2018        PMID: 29571786     DOI: 10.1016/j.ejrad.2018.02.021

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Lymphatics, Long a Mystery-Primed to Make History.

Authors:  Bill S Majdalany
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 2.  Nodal and Pedal MR Lymphangiography of the Central Lymphatic System: Techniques and Applications.

Authors:  Claus Christian Pieper
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 3.  Contemporary lymphatic interventions for post-operative lymphatic leaks.

Authors:  Bill S Majdalany; Ghassan El-Haddad
Journal:  Transl Androl Urol       Date:  2020-01

4.  Dynamic contrast-enhanced magnetic resonance lymphangiography in pediatric patients with central lymphatic system disorders.

Authors:  Veronica Bordonaro; Paolo Ciancarella; Paolo Ciliberti; Davide Curione; Carmela Napolitano; Teresa Pia Santangelo; Gian Luigi Natali; Massimo Rollo; Paolo Guccione; Luciano Pasquini; Aurelio Secinaro
Journal:  Radiol Med       Date:  2021-01-04       Impact factor: 3.469

5.  Dynamic Contrast Magnetic Resonance Lymphangiography Localizes Lymphatic Leak to the Duodenum in Protein-Losing Enteropathy.

Authors:  Jefferson N Brownell; David M Biko; Petar Mamula; Ganesh Krishnamurthy; Fernando Escobar; Abhay Srinivasan; Pablo Laje; David A Piccoli; Erin Pinto; Christopher L Smith; Yoav Dori
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-01-01       Impact factor: 3.288

Review 6.  Chylous Ascites and Lymphoceles: Evaluation and Interventions.

Authors:  Ernesto Santos; Amgad M Moussa
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.